<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02412644</url>
  </required_header>
  <id_info>
    <org_study_id>AP-CL-PSOR-PI-004893</org_study_id>
    <nct_id>NCT02412644</nct_id>
  </id_info>
  <brief_title>Apremilast 30mg Bid With Narrowband UVB in the Treatment of Plaque Psoriasis</brief_title>
  <official_title>Efficacy and Safety of Combining Apremilast 30mg Bid With Narrowband UVB in the Treatment of Moderate-to-severe Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Psoriasis Treatment Center of Central New Jersey</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Psoriasis Treatment Center of Central New Jersey</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      12 weeks open label with Otezla® and NUVB, followed by 6 month double blind Otezla®
      (apremilast) or placebo to subjects who obtain PASI 75 at week 12 of phototherapy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective: To evaluate the effectiveness of Otezla (apremilast®) in promoting
      maintenance of response in those subjects who obtained PASI-75 at week 12 of phototherapy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Endpoint Proportion of subjects maintaining PASI-75 six months after discontinuation of nUVB</measure>
    <time_frame>36weeks</time_frame>
    <description>Proportion of subjects maintaining PASI-75 six months after discontinuation of nUVB</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Endpoints Proportion of subjects achieving Psoriasis Area Severity Index score (PASI) 75 response at week 12</measure>
    <time_frame>12WEEKS</time_frame>
    <description>Secondary Endpoints:
Proportion of subjects achieving Psoriasis Area Severity Index score (PASI) 75 response at week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Endpoints PASI 75 at week 36</measure>
    <time_frame>36 weeks</time_frame>
    <description>PASI 75 at week 36</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Endpoints PASI 90 at week 36</measure>
    <time_frame>36 weeks</time_frame>
    <description>PASI 90 at week 36</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Endpoints PGA 0 or 1 at week 36</measure>
    <time_frame>36 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Endpoints DLQI change from baseline to week 12, change from baseline to week 36</measure>
    <time_frame>36 weeks</time_frame>
    <description>DLQI change from baseline to week 12, change from baseline to week 36</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Endpoints VAS pain and Vas itch change from baseline to week 36</measure>
    <time_frame>36 weeks</time_frame>
    <description>VAS pain and Vas itch change from baseline to week 36</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Endpoints Serious Adverse Events (SAE's) and Events of Medical Interest (EMI's)</measure>
    <time_frame>36 weeks</time_frame>
    <description>Serious Adverse Events (SAE's) and Events of Medical Interest (EMI's)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Plaque Psoriasis</condition>
  <arm_group>
    <arm_group_label>Apremilast</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>apremilast 30mg bid for 12 weeks. After 12 weeks apremilast 30 mg bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>apremilast</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>after week 12 PASI 75 responders receive ampremilast 30mg bid or placebo bid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>apremilast</intervention_name>
    <arm_group_label>Apremilast</arm_group_label>
    <arm_group_label>apremilast</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: Subjects must meet the following criteria to be enrolled in this study:

          1. Male or female adult ≥ 18 years of age;

          2. Diagnosis of chronic plaque-type

          3. Moderate to severe plaque type psoriasis as defined at baseline by:

               -  PASI score of 12 or greater,

               -  PGA score of 3 or greater

               -  BSA affected by plaque-type psoriasis of 10% or greater,

          4. Able and willing to give written informed consent prior to performance of any
             study-related procedures

        Exclusion Criteria:

        Subjects who meet any of the following criteria will be excluded from participation in this
        study:

          1. Forms of psoriasis other than chronic plaque-type (e.g., pustular, erythrodermic,
             and/or guttate psoriasis) or drug induced psoriasis

          2. Subjects with previous exposure to apremilast

          3. Malignancy or history of malignancy, except for:

               -  treated [ie, cured] basal cell or squamous cell in situ skin carcinomas;

               -  treated [ie, cured] malignancy with no evidence of recurrence within the previous
                  5 years.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Psoriasis Treatment Center of Central New Jersey</name>
      <address>
        <city>East Windsor</city>
        <state>New Jersey</state>
        <zip>08520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 23, 2015</study_first_submitted>
  <study_first_submitted_qc>April 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2015</study_first_posted>
  <last_update_submitted>July 19, 2016</last_update_submitted>
  <last_update_submitted_qc>July 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apremilast</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>March 2, 2017</submitted>
    <returned>April 13, 2017</returned>
    <submitted>December 21, 2017</submitted>
    <returned>January 19, 2018</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

